Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-05-10
2011-05-10
McGarry, Sean R (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C536S024100, C435S006120, C514S04400A
Reexamination Certificate
active
07939652
ABSTRACT:
The invention relates to a double-stranded compound, preferably an oligoribonucleotide (siRNA), which down-regulates the expression of a human TGaseII gene at the post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from a fibrotic disease such as pulmonary, kidney and liver fibrosis or ocular, scarring comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The invention also relates to treatment of fibrotic and other diseases by use of antibodies to TGaseII polypeptide.
REFERENCES:
patent: 6506559 (2003-01-01), Fire et al.
patent: 6773916 (2004-08-01), Thiel et al.
patent: 7452987 (2008-11-01), Giese et al.
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0197310 (2005-09-01), Mor et al.
patent: 2007/0021360 (2007-01-01), Nyce et al.
patent: 1144623 (2001-10-01), None
patent: 2 397 818 (2005-03-01), None
patent: WO 98/04245 (1998-02-01), None
patent: WO 02/44321 (2002-06-01), None
patent: WO 02/44321 (2002-06-01), None
patent: WO 02/085308 (2002-10-01), None
patent: WO 02/85309 (2002-10-01), None
patent: WO 03/070197 (2003-08-01), None
patent: WO 03/070197 (2003-08-01), None
patent: WO 2004/009769 (2004-01-01), None
patent: WO 2004/113496 (2004-12-01), None
patent: WO 2004/113496 (2004-12-01), None
Vickers et al The Journal of Biological Chemistry vol. 278(9):7108-7118, Feb. 28, 2003.
Fesus L, et al. (2002) “Transglutaminase 2: an enigmatic enzyme with diverse functions,”Trends in Biochem. Sci.; 27(10):534-539.
Mastroberardino PG, et al., (2002) “‘Tissue’ transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease,”Cell Death and Differentiation, 9(9):873-880.
Zhu J, et al., (1999) “Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis,”Gastroenterology, 5:1198-1204.
Supplementary European Search Report issued by the European Patent Office on Jan. 22, 2008 in connection with European Application No. 05703145.2-2405.
Edited by Beers et al., (1999), “The Merck Manual of Diagnosis and Therapy”, 17 ed. Merck Research Laboratories, Whitehouse Station, NJ, Chapter 222, pp. 1845-1847.
Examination Report issued by the European Patent Office on Jun. 2, 2008 in connection with European Application No. 05703145.2.
Examination Report issued by the European Patent Office on Feb. 26, 2009 in connection with European Application No. 05703145.2.
Communication pursuant to Rule 71(3) EPC issued by the European Patent Office on Jun. 2, 2010 in connection with European Patent Application No. 05703145.2.
Response to the Communication Under Rule 71(3) EPC and Request for Amendments pursuant to Rule 71(4) EPC submitted Sep. 7, 2010 in connection with European Patent Application No. 05703145.2.
Bernstein, E. et al. (2001) “Role for a Bidentate Ribonuclease in the Initiation Step of RNA Interference”Nature409:363-366.
Bartel, P. D. (2004) “MicroRNAs: Genomics, Biogenesis, Mechanism, and Function”Cell116:281-297.
Chalk, M. A. et al. (2004) “Improved and Automated Prediction of Effective siRNA”Biochemical and Biophysical Research Communication319:264-274.
Chen, J.S.K. et al. (1999) “Tissue Transglutaminase: An Enzyme with a Split Personality”Int. Jour. Of Biochem.&Cell Biology31:817-836.
Citron, B.A. et al. (2002) “Protein Crosslinking, Tissue Transglutaminase, Alternative Splicing and Neurodegeneration”Neurochemistry International40:69-78.
Dieterich, W. et al. (1997) “Identification of Tissue Transglutaminase as the Autoantigen of Celiac Disease”Nature Medicine3(7):797-801.
Elbashir, S.M. et al. (2001) “Duplexes of 21-Nucleotides RNAs Mediate RNA Interference in Cultured Mammalian Cells”Nature411:494-498.
Elbashir SM, et al. (2001) Functional anatomy of siRNAs for mediating efficient RNAi inDrosophila melanogasterembryo lysate.EMBO J. 20(23):6877-6888.
Fire, A. et al. (1998) “Potent and Specific Genetic Interference by Double-Stranded RNA inCaenorhabditis elegans” Nature391:806-811.
Fraij BM, et al. (1992) A retinoic acid-inducible mRNA from human erythroleukemia cells encodes a novel tissue transglutaminase homologue.J. Biol. Chem. 267(31):22616-22623.
Greenberg, B. (2001) “Treatment of Heart Failure: State of the Art and Prospective”Journal of Cardiovascular Pharmacology38:S59-S63.
Grenard, P. (2001) “Transglutaminase-Mediated Cross-Linking is Involved in the Stabilization of Extracellular Matrix in Human Liver Fibrosis”Journal of Hepatology35:367-375.
Griffin, M. et al. (1979) “Chances in Transglutaminase Activity in an Experimental Model of Pulmonary Fibrosis Induced by Paraquat”Br. J. Exp. Path. 60:653-661.
Hwang, K.C. et al. (1996) “α1-Adrenergic Receptor Coupling With Ghin the Failing Human Heart”American heart Association, Inc. 94:718-726.
Hannon, G.J. (2002) “RNA Interference”Nature418:244-251.
Johnson, T.S. et al. (1997) “The Role of Transglutaminase in the Rat Subtotal Nephrectomy Model of Renal Fibrosis”J. Clin.Invest. 99(12):2950-2960.
Johnson, T.S. et al. (1999) “Transglutaminase Transcription and Antigen Translocation in Experimental Renal Scarring”J. Am. Soc. Nephrol. 10:2146-2157.
Karpuj, M.V. et al. (2002) “Prolonged Survival and Decreased Abnormal Movements in Transgenic Model of Huntington Disease, with Administration of the Transglutaminase Inhibitor Cystamine”Nature Medicine8(2):143-149.
Lesort, M. et al. (2000) “Tissue Transglutaminase: A Possible Role in Neurodegenerative Diseases”Progress in Neurobiology61:439-463.
Levenkova, N. et al. (2004) “Gene Specific siRNA Selector”Bioinformatics20(3):430-432.
McManus, T. M. (2002) “Gene Silencing in Mammals by Small Interfering RNAs”Nature Reviews3:737-747.
Mirza, A. et al. (1997) “A Role for Tissue Transglutaminase in Hepatic Injury and Fibrogenesis, and its Regulation by NF-kB”The American Physiological Society281-288.
Piacentini, M. et al. (2002) “Transglutaminase Overexpression Sensitizes Neuronal Cell Lines to Apoptosis by Increasing Mitochondrial Membrane Potential and Cellular Oxidative Stress”Journal of Neurochemistry81:1061-1072.
Reich, S.J., et al. (2003) “Small Interfering RNA (siRNA)TargetingVEGFEffectively Inhibits Ocular Neovascularization in a Mouse Model”Molecular Vision9:210-216.
Shin, D.M. et al. (2004) “Cell Type-Specific Activation of Intracellular Transglutaminase 2 by Oxidative Stress or ultraviolet Irradiation”The Journal of Biological Chemistry279(15):15032-15039.
Shridas, P. et al. (2001) “Transglutaminase-Mediated Cross-Linking of α-Crystallin: Structural and Functional Consequences” FEBS Letters 499:245-250.
Sioud, M. et al. “Potential Design Rules and Enzymatic Synthesis of siRNAs”Methods in Molecular Biology252:457-468, 2004.
Soutschek, J. et al. (2004) “Therapeutic Silencing of an Endogeneous Gene by Systemic Administration of Modified siRNAs”Nature432:173-178.
Takeuchi, N. et al. (2000) “Crystallin Proteins in Lenses of Hereditary Cataractous Rat, ICR/f”Biol. Pharm. Bull. 23(3):283-290.
Tolentino, M.J. (2004) “Intravitreal Injection of Vascular Endothelial Growth Factor Small Interfering RNA Inhibits Growth and Leakage in a Nonhuman Primate, Laser-Induced Model of Choroidal Neovascularization”Retina, The Journal of Retinal and Vitreous Disease24(1):132-138.
Ui-Tei, K. et al. (2004) “Guidelines for the Selection
Feinstein Elena
Mor Orna
Cooper & Dunham LLP
McGarry Sean R
Quark Pharmaceuticals Inc.
White John P.
LandOfFree
Oligoribonucleotides and methods of use thereof for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligoribonucleotides and methods of use thereof for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligoribonucleotides and methods of use thereof for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2667229